To see the other types of publications on this topic, follow the link: Overactive Bladder Nocturia Incontinence.
Journal articles on the topic 'Overactive Bladder Nocturia Incontinence'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Overactive Bladder Nocturia Incontinence.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Subhan, Sana, Syed Imran Ahmad, Muhammad Hammad Ali Mithani, Aftab Ahmed Mirza Baig, Muhammad Kashif, and Muhammad Arif Siddiqui. "Effects of transcutaneous tibial nerve stimulation for overactive bladder symptoms in adults: A randomized controlled trial." Rehabilitation Journal 07, no. 03 (2023): 36–41. http://dx.doi.org/10.52567/trehabj.v7i03.7.
Full textAbstract:
Background: Overactive bladder (OAB) is characterized by urinary urgency, frequency, and nocturia, often accompanied by urinary incontinence. OAB significantly impacts the quality of life of affected individuals. Transcutaneous Tibial Nerve Stimulation (TTNS) is a non-invasive treatment option used to manage overactive bladder (OAB) symptoms. Objective: to determine the effects of Transcutaneous Tibial Nerve Stimulation on overactive bladder symptoms in adults. Methods: A randomized controlled trial was held at the Sindh Institute of Physical Medicine and Rehabilitation with a non-probability purposive sampling technique. After screening for inclusion criteria 60 patients were randomly allocated into two Group A received Transcutaneous tibial nerve stimulation (TTNS) combined with traditional physiotherapy, while Group B just received traditional physiotherapy. Both interventions were given for six weeks. The overactive Bladder Symptom Score was used as an outcome measure tool. Results: Group A improved in all OAB parameters, including daytime frequency (p=0.008), nocturia (p=0.006), urinary urgency (p=0.002), and urge urinary incontinence (p=0.008) with a significant improvement p<0.05. All OABSS parameters in group B also showed a considerable improvement (p<0.05), except for urge urinary incontinence (p=0.08). Conclusion: the daytime frequency, nocturia, and urgency parameters of the overactive bladder symptoms score significantly decreased in both the TTNS+PFM group and the Traditional physiotherapy group. However, urge urinary incontinence showed significant improvement only in the TTNS+PFM group.
2
Chuang, Po-Heng, Yi-Huei Chang, Po-Jen Hsiao, and Eric Chieh-Lung Chou. "Diagnostic Potential of Low Serum Platelet, Albumin and Prolong PT-INR for Overactive Bladder and Nocturia in Chronic Hepatitis-Related Liver Cirrhosis." Journal of Clinical Medicine 10, no. 13 (2021): 2838. http://dx.doi.org/10.3390/jcm10132838.
Full textAbstract:
Overactive bladder (OAB) is defined as urgency, usually with frequency, nocturia, and incontinence. Patients with liver cirrhosis often present with urinary complaints. The possible reason for this is fluid redistribution, which may induce OAB resulting from portal hypertension and ascites. We conducted this study to investigate predictors of OAB in cirrhotic patients. A total of 164 patients with chronic viral hepatitis-related liver cirrhosis were enrolled and 158 (96.3%) completed the Overactive Bladder Symptoms Score (OABSS) questionnaire. Age, severity of liver cirrhosis, comorbidities, serum sodium level, use of diuretics, body mass index and renal function were also recorded. In the study cohort, the prevalence of OAB was 31.01% and the prevalence of urge incontinence (OAB wet) was 18.3%. Patients with an urgency score ≥2 in OABSS had a significantly lower platelet level (p = 0.025) regardless of the use of diuretics. In addition, 98 patients (62%) with nocturia and 29 patients (18%) with urge incontinence had significantly lower levels of serum albumin (p = 0.028 and 0.044, respectively). In conclusion, patients with liver cirrhosis have a high prevalence of overactive bladder. A low platelet and low serum albumin level in these patients may be predictors for overactive bladder. And longer PT-INR is also a possible biomarker for nocturia.
3
ABREU, Glícia Estevam de, Eneida Regis DOURADO, Danielle de Novais ALVES, Milly Queiroz de ARAUJO, Natália Souza Paes MENDONÇA, and Ubirajara BARROSO JUNIOR. "FUNCTIONAL CONSTIPATION AND OVERACTIVE BLADDER IN WOMEN: A POPULATION-BASED STUDY." Arquivos de Gastroenterologia 55, suppl 1 (2018): 35–40. http://dx.doi.org/10.1590/s0004-2803.201800000-46.
Full textAbstract:
ABSTRACT BACKGROUND: An association between urinary disorders and functional constipation has been registered in children and adults, with functional constipation being a common complaint in individuals with overactive bladder. OBJECTIVE: To evaluate the prevalence of functional constipation, overactive bladder and its dry/wet subtypes in women and to determine which bowel symptoms predict overactive bladder. METHODS: A cross-sectional study of women randomly approached in public spaces. Exclusion criteria: neurological/anatomical abnormalities of the bowel or urinary tract. Constipation was defined as ≥2 positive symptoms of those listed in the Rome criteria. Urinary abnormalities (frequent urination, urgency, incontinence, nocturia) were defined by a score ≥2 in the respective item of the International Consultation on Incontinence Questionnaire - Overactive Bladder. Dry overactive bladder was defined as urgency without incontinence, while wet overactive bladder included incontinence. RESULTS: A total of 516 women with a mean age of 35.8±6 years were interviewed. Rates of functional constipation, overactive bladder, dry overactive bladder and wet overactive bladder were 34.1%, 15.3%, 8.9% and 6.4%, respectively. Functional constipation was associated with overactive bladder and dry overactive bladder, with functional constipation predicting dry overactive bladder (OR=2.47). Quality of life was poorer in constipated women compared to non-constipated and even worse in constipated women with wet overactive bladder (median 22.5; 95%CI: 17.25-35.25). Manual maneuvers were significantly associated with both overactive bladder subtypes. Independent predictive factors for overactive bladder were manual maneuvers (OR=2.21) and <3 defecations/week (OR=2.18), with the latter being the only predictive factor for dry overactive bladder (OR=3.0). CONCLUSION: Functional constipation is associated with overactive bladder and its dry subtype, particularly in the younger population. In addition, this association is responsible for lower quality of life scores, especially when urinary incontinence is present. The presence of manual maneuvers and less than three defecations per week should direct us to look for overactive bladder.
4
Kotowicz, Zuzanna, Jakub Pabiś, and Piotr Podgórski. "An examination of Overactive Bladder Syndrome: present comprehension, methods of treatment, and innovative approaches." Journal of Education, Health and Sport 64 (March 22, 2024): 106–17. http://dx.doi.org/10.12775/jehs.2024.64.007.
Full textAbstract:
Introduction
 Overactive bladder syndrome poses a major challenge to healthcare, as an accurate estimate of its prevalence proves elusive due to patients' reluctance to disclose the embarrassing symptoms that accompany the disorder. Symptoms such as frequent urination, nocturia and incontinence are not only distressing but also significantly impair patients' quality of life. Effective diagnosis and treatment require the identification of associated risk factors, and behavioural therapy serves as the basis for implementing lifestyle modifications. This comprehensive study delves into the managing of overactive bladder syndrome, shedding light on recent advances in diagnosis and treatment. In particular, it looks at the integration of minimally invasive techniques and new medications that promise to not only alleviate symptoms, but also significantly improve patients' overall quality of life. 
 Aim of the study
 This review aims to identify risk factors, symptoms, methods of diagnosis of overactive bladder syndrome and solutions in its treatment process. The main aim is to present treatment methods with the latest developments.
 Material and method
 This article presents the current state of knowledge about overactive bladder syndrome in various scientific articles. Publications describing overactive bladder syndrome, its symptoms, impact on life comfort and treatment options, including recent reports in the field, were reviewed using the PubMed platform. The search included the keywords ‘overactive bladder’, ‘urgency urinary incontinence’, ‘anticholinergics’, ‘mirabegron’, ‘nocturia’.
5
Mehlman, Kaylee, Victoria Nalls, and Douglas Wessel. "Complicated Overactive Bladder Management." Senior Care Pharmacist 40, no. 1 (2025): 10–17. https://doi.org/10.4140/tcp.n.2025.10.
Full textAbstract:
These case studies review the treatment of patients with overactive bladder (OAB), a chronic condition presenting with urinary urgency, often occurring with frequency and nocturia, which may or may not be associated with urinary incontinence. Patients with OAB can have multiple clinical factors to consider when selecting the optimal therapy, and this treatment series provides examples of approaches to balance treatment selection with other comorbidities and patient expectations.
6
Wallace, Karen M., and Marcus J. Drake. "Overactive bladder." F1000Research 4 (December 7, 2015): 1406. http://dx.doi.org/10.12688/f1000research.7131.1.
Full textAbstract:
Overactive bladder syndrome is highly prevalent, and increasingly so with aging. It is characterized by the presence of urinary urgency, and can be associated with incontinence, increased voiding frequency, and nocturia. Assessment needs to exclude serious medical disorders that might present with similar symptoms, and a bladder diary is an invaluable part of understanding the presentation. Initial management is conservative, comprising education, bladder training, and advice on fluid intake. Drug therapy options include antimuscarinic medications and beta-3 adrenergic receptor agonists. Persistent overactive bladder syndrome, despite initial therapy, requires a review of the patient’s understanding of conservative management and compliance, and adjustment of medications. For refractory cases, specialist review and urodynamic testing should be considered; this may identify detrusor overactivity or increased filling sensation, and needs to exclude additional factors, such as stress incontinence and voiding dysfunction. Botulinum neurotoxin-A bladder injections can be used in severe overactivity, provided the patient is able and willing to do intermittent self-catheterisation, which is necessary in about 5% of treated patients. Sacral nerve stimulation and tibial nerve stimulation are other approaches. Major reconstructive surgery, such as augmentation cystoplasty, is rarely undertaken in modern practice but remains a possibility in extreme cases.
7
Hwang, Ye-Chae, Hye-Jin Lee, Hye-Min Heo, et al. "Clinical Report of Baliao Electroacupuncture Treatment on a Stroke Patient Suffering from a Neurogenic Overactive Bladder." Journal of Internal Korean Medicine 43, no. 1 (2022): 90–103. http://dx.doi.org/10.22246/jikm.2022.43.1.90.
Full textAbstract:
Objective: The purpose of this case study is to report the effectiveness of Baliao acupoints electro-acupuncture treatment on a neurogenic overactive bladder induced by stroke.Method: A patient suffering from middle cerebral artery infarction was diagnosed with a neurogenic overactive bladder and treated by Korean medicine, including electro-acupuncture on Baliao acupoints six times per week. The evaluation was performed by monitoring urinary frequency and using the Korean versions of the Overactive Bladder Symptom Score (OABSS) and Urinary Incontinence Quality of Life (I-QoL).Results: After 27 days of electro-acupuncture treatment, the OABSS score improved from 6 to 3. The I-QoL total score improved from 60 to 87. The patient also showed a decrease in nocturia frequency.Conclusion: This case suggests that electro-acupuncture on Baliao acupoints can be effective for overactive bladders due to supra-pontine lesions.
8
Avnish, Kaur Jabbal, Maji Aritra, and Sehgal Chandni. "Overactive Bladder- Thin End of the Wedge in Perimenopausal Women: A Case Control Study." International Journal of Pharmaceutical and Clinical Research 16, no. 3 (2024): 1699–702. https://doi.org/10.5281/zenodo.11181592.
Full textAbstract:
<strong>Background:</strong> Globally, urinary incontinence impacts approximately 200 million individuals, with women being disproportionately affected at twice the rate of men. The International Continence Society (ICS) defines Overactive Bladder (OAB) as a symptom complex that includes urinary urgency, potentially accompanied by urge incontinence, and typically presents with increased frequency and nocturia. OAB substantially diminishes various aspects of life, such as work, sleep, sexual intimacy, and interpersonal relationships. Notably, urge incontinence, a component of OAB, significantly degrades health-related quality of life (HRQL). <strong>Methodology:</strong> This case-control study involved 100 perimenopausal women, split into two groups: 50 participants displaying genitourinary symptoms formed the case group, and 50 asymptomatic individuals served as controls. We employed a structured questionnaire to assess their genitourinary issues. <strong>Result:</strong> Findings from the study indicated that while urge incontinence and urgency were exclusively noted in symptomatic women (cases), other genitourinary issues such as frequency, nocturia, and vasomotor symptoms were similarly prevalent in both cases and controls. <strong>Conclusion:</strong> The study reveals that even perimenopausal women who are asymptomatic may experience urogenital symptoms, highlighting a pervasive lack of awareness and understanding of overactive bladder issues within the community.
9
Tamburro, Fabiola R., Pietro Castellan, Fabio Neri, et al. "Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience." Urologia Journal 85, no. 4 (2018): 163–68. http://dx.doi.org/10.1177/0391560318759258.
Full textAbstract:
Objective: Onabotulinumtoxin-A has been approved for wet overactive bladder refractory to anticholinergics in randomised controlled trials; however, data from real-life practice are scarce. This study was designed to assess the efficacy of intravesical onabotulinumtoxin-A injections, focusing on health status, urinary symptoms and subjective satisfaction. Methods: Data from consecutive patients with overactive bladder-refractory to anticholinergics treated with onabotulinumtoxin-A were prospectively collected and analysed. Standard doses (100–150 U) were used, followed by repeat sessions when clinical benefits diminished. Efficacy and safety of repeat onabotulinumtoxin-A administrations were assessed at 12-week post-injection. Clinical parameters evaluated were: change in the magnitude and frequency of incontinence, urgency and nocturia episodes, change in the number of pads used and procedural complications. Quality of life was evaluated using the 36-Item Short-Form Health Survey, Overactive Bladder Screener and Treatment Benefit Scale questionnaires. Results: Consecutive overactive bladder-refractory to anticholinergics patients ( n = 22) (median duration of oral therapy: 10 months) were enrolled. No intraoperative complications occurred, but two urinary retention cases were recorded. Forty-five percent of patients (10/22) were re-treated (median duration of perceived benefits: 18 months, range: 8–55 months). The number of urinary incontinence, frequency and nocturia episodes, and pads used went from 3.6, 11.3, 2.7 and 2.4 preoperatively to 1.0, 5.8, 0.7 and 0.7 postoperatively ( p < 0.005). Quality of life (36-Item Short-Form Health Survey) was significantly improved and symptom scores (Overactive Bladder Screener) were reduced, from 34.5 to 17.1 at week 12 ( p < 0.05). Eighty-seven percent of patients indicated improvement/great improvement in their condition (Treatment Benefit Scale). Conclusion: Intradetrusor injections of onabotulinumtoxin-A in patients with overactive bladder-refractory to anticholinergics significantly improved health status and urinary symptoms, with high subjective satisfaction.
10
Jaya Satyal, Pradeep K.C, Rakesh Shrestha, et al. "Effect of Electroacupuncture in Neurogenic Bladder: A Quasi-Experimental Study." Dinkum Journal of Medical Innovations 3, no. 12 (2024): 806. https://doi.org/10.71017/djmi.3.12.d-0352.
Full textAbstract:
Neurogenic bladder (NB) is the dysfunction of either the urinary bladder, bladder neck or its sphincters due to diseases of the peripheral or central nervous system involved in the control of micturition or urination. There are two types of neurogenic bladder. One is overactive bladder and another is underactive bladder. Acupuncture has certain effective role in treating bladder dysfunction including urinary retention and incontinence. This study used to explore the effectiveness of electroacupuncture in patients with neurogenic bladder and compare the difference in improvement of urological symptoms of overactive and underactive bladder symptoms along with quality of life assessed by NBSS score between the case and control group. This was a quasi-experimental study with non-probability convenient sampling. The overactive bladder issues along with incontinence were taken care by parameters (Day time frequency, saturation of pads, number of pads, nocturnal incontinence, skin problem, limits of activities, interval without leakage, liquid restriction) of NBSS score and the results were found to statistically significant (p<0.05) on case group.The underactive bladder issues along with storage and voiding problems were taken care by parameters (Frequency of urge, Urgency, Nocturia, Longest interval, post void fullness, stream, and straining) of NBSS score and the results were found to statistically significant (p<0.05) on case group.The consequences parameter (Pain and UTI) of neurogenic bladder for both underactive and overactive bladder were found to statistically significant (p<0.05) on case group as compared with control group.The quality of life parameter from NBSS score was statistically significant (p<0.05) in case group as compared with control group.The results of the present study suggest that for thirty minutes of acupuncture in Sanyinjiao (SP6), Yinlingquan (SP9), Qugu (CV2), Zhongji (CV3), Qihai (CV6), Shenshu (BL23), Pangguanshu (BL28), Baihui (GV20), Zhaohai (KL6), Zhongliao (BL33), Xialiao (BL34), Guanyuanshu (BL26) and electroacupuncture in Ciliao (BL23 and Shuidao (ST28) six times a week for three weeks along with conventional management is very effective in improving symptoms of both overactive and underactive bladder issues. Evidence suggests that EA is the vital components in treating NB issues so it should be taken into considerations while treating neurogenic bladder problems.
11
Heyns, C. F., and G. W. Rienhardt. "Guidelines for the Treatment of Urinary Incontineence and Overactive Bladder." South African Family Practice 25, no. 2 (2002): 6. http://dx.doi.org/10.4102/safp.v25i2.2071.
Full textAbstract:
Urinary incontinence (UI) is the involuntary leakage of urine, while overactive bladder (OAB) is characterised by frequency, nocturia and urgency, with or without incontinence. This paper provides guidelines for the management of UI and OAB, focusing on primary health care. Although UI and OAB negatively impact on the patients quality of life more severely than diabetes mellitus or rheumatoid arthritis, surveys have shown that more than 60% of persons with UI never mention their problem to a doctor or nurse.Therefore, the primary care setting is ideal for screening, basic evaluation, and initial management of UI and OAB. A focused history and examination will usually enable the practitioner to distinguish between the different types of incontinence, such as stress, urge (overactive bladder), mixed, overflow and continuous incontinence. It should include a vaginal examination and cough test in women, rectal examination in men, dipsticks urinalysis, and assessment of the post-void residual urine. A bladder diary filled in by the patient can be very useful. There may be reversible conditions causing or contributing to the patients incontinence, such as urinary tract infection. In certain cases referral to a specialist is required, e.g. patients with incontinence after previous surgery, or associated with pain or hematuria. However, many patients with symptoms of OAB or UI can be eff ectively treated at the primary care level. Management options include lifestyle modification (e.g. smoking cessation and weight loss), pelvic floor exercises, and pharmacotherapy. Overactive bladder can be treated with muscarinic antogonists such as tolterodine and oxybutinin.
12
Navarro, Junior J. Araiza J. Araiza, Raúl D. Lara Sánchez, Oyuki A. Morales Uscanga, María I. Tolentino Sosa, Fernando López Reyes, and Jorge A. Barbabosa Vilchis. "Refractory hyperactive bladder treated with sacral neuromodulator: case report and literature review." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 7, no. 7 (2018): 2937. http://dx.doi.org/10.18203/2320-1770.ijrcog20182910.
Full textAbstract:
The overactive bladder syndrome is a chronic medical condition that affects the quality of life of patients whether men or women, has a prevalence of 16.5%, however, it is known to increase with age, affecting up to 25% of women older than 65 years and up to 80% in the elderly. More than 90% of cases have no apparent cause. The OAB (Overactive Bladder) It is a condition with characteristic symptoms of urinary urgency, usually accompanied by frequency and nocturia, with or without urge incontinence, in the absence of urinary tract infection or other obvious pathology. The different therapeutic steps are not always sufficient to restore the quality of life.
13
Nia, Tri Mulyani, Irmayanti Wiwiet, and Kurniasari Dian. "The Medical Rehabilitation of Overactive Bladder after Transurethral Resection of the Prostate: A Case Report." RA JOURNAL OF APPLIED RESEARCH 09, no. 04 (2023): 21 3–220. https://doi.org/10.5281/zenodo.7830639.
Full textAbstract:
<strong>Introduction:</strong> Overactive bladder is a syndrome of increased urinary frequency and nocturia with or without incontinence in absence of obvious pathology. Transcutaneous Tibial Nerve Stimulation (TTNS) is one of the neuromodulation used to treat overactive bladder. We report the medical rehabilitation program in overactive bladder post-Transurethral Resection of The Prostate (TURP). The medical rehabilitation program consisted of pelvic floor muscle exercise and TTNS that may reduce the overactive bladder symptoms. This study aims to determine whether TTNS and pelvic floor muscle exercise will reduce overactive bladder symptoms after TURP. <strong>Case Presentation:</strong> a 40-year-old Asian man who developed overactive bladder symptoms after TURP had the medical rehabilitation program consisting of pelvic floor muscle exercise and TTNS. The pelvic floor exercise was given twice a day and TTNS was given twice a week for 12 cycles and repeated for 12 cycles. He was followed up by Over Active Bladder Symptoms Score (OABSS) to assess the severity of symptoms. <strong>Conclusion:</strong> The medical program rehabilitation that consisted of pelvic floor muscle exercise and TTNS reduced 50% in the severity of overactive bladder symptoms after TURP. No complications have been reported. Need further research to know the definitive result.Overactive Bladder; Transurethral Resection of the Prostate; Transcutaneous Tibial Nerve Stimulation; Pelvic Floor
14
Kavia, RBC, D. De Ridder, CS Constantinescu, CG Stott, and CJ Fowler. "Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis." Multiple Sclerosis Journal 16, no. 11 (2010): 1349–59. http://dx.doi.org/10.1177/1352458510378020.
Full textAbstract:
Background: Bladder dysfunction is a common feature of multiple sclerosis (MS). Objective: In this study we aimed to assess the efficacy, tolerability and safety of Sativex® (nabiximols) as an add-on therapy in alleviating bladder symptoms in patients with MS. Methods: We undertook a 10-week, double-blind, randomized, placebo-controlled, parallel-group trial in 135 randomized subjects with MS and overactive bladder (OAB). Results: The primary endpoint was the reduction in daily number of urinary incontinence episodes from baseline to end of treatment (8 weeks). Other endpoints included incidence of nocturia and urgency, overall bladder condition (OBC), daytime frequency, Incontinence Quality of Life (I-QOL), Patient’s Global Impression of Change (PGIC) and volume voided. The primary endpoint showed little difference between Sativex and placebo. Four out of seven secondary endpoints were significantly in favour of Sativex: number of episodes of nocturia (adjusted mean difference -0.28, p = 0.010), OBC (-1.16, p = 0.001), number of voids/day (-0.85, p = 0.001) and PGIC ( p = 0.005). Of the other endpoints, number of daytime voids was statistically significantly in favour of Sativex (-0.57, p = 0.044). The improvement in I-QOL was in favour of Sativex but did not reach statistical significance. Conclusions: Although the primary endpoint did not reach statistical significance, we conclude that Sativex did have some impact on the symptoms of overactive bladder in patients with MS, providing evidence of some improvement in symptoms associated with bladder dysfunction in these subjects.
15
Araklitis, George, Georgina Baines, Ana Sofia da Silva, Dudley Robinson, and Linda Cardozo. "Recent advances in managing overactive bladder." F1000Research 9 (September 11, 2020): 1125. http://dx.doi.org/10.12688/f1000research.26607.1.
Full textAbstract:
Overactive bladder syndrome (OAB) is defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology. In this review, we focus on recent advances in the management of OAB. We examine the evidence on the effect of anticholinergic load on OAB patients. Advances in medical treatment include a new beta-3 agonist, vibegron, which is thought to have fewer drug interactions than mirabegron. Treatment of genitourinary syndrome of the menopause with oestrogens and ospemifene have also shown promise for OAB. Botulinum toxin has been shown to be an effective treatment option. We discuss the new implantable neuromodulators that are on the market as well as selective bladder denervation and laser technology.
16
Arruda, Raquel, Claudia Takano, Manoel Girão, Jorge Haddad, Gabriel Aleixo, and Rodrigo Castro. "Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials." Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics 40, no. 04 (2018): 225–31. http://dx.doi.org/10.1055/s-0038-1642631.
Full textAbstract:
AbstractWe performed a systematic review and meta-analysis of randomized placebo-controlled trials that studied non-neurogenic overactive bladder patients who were treated with 100 units of onabotulinumtoxinA or placebo. The primary purpose of our study was to evaluate the clinical effectiveness with regard to urinary urgency, urinary frequency, nocturia, and incontinence episodes. Our secondary purpose consisted of evaluating the adverse effects. Our initial search yielded 532 entries. Of these, seven studies met all the inclusion criteria (prospective, randomized, placebo-controlled studies, ≥ 3 points on the Jadad scale) and were selected for analysis. For all primary endpoints, the toxin was more effective than placebo (p < 0.0001; 95% confidence interval [95CI]), namely: urgency (mean difference = -2.07; 95CI = [-2.55–1.58]), voiding frequency (mean difference = -1.64; 95CI = [-2.10–1.18]), nocturia (mean difference = -0.25; 95CI = [-0.39–0.11]) and incontinence episodes (mean difference = -2.06; 95CI= [-2.60–1.52]). The need for intermittent catheterization and the occurrence of urinary tract infection (UTI) were more frequent in patients treated with onabotulinumtoxinA than in patients treated with placebo (p < 0.0001). Compared with placebo, onabotulinumtoxinA had significantly and clinically relevant reductions in overactive bladder symptoms and is associated with higher incidence of intermittent catheterization and UTI.
17
Pradhan, Tarun, Baburam Dixit Thapa, Pritha Basnet, Surya Prasad Rimal, Tulasha Basnet, and Mohan Chandra Regmi. "Evaluation of Lower Urinary Tract Symptoms (LUTS): Severity Score and Symptom Association." Birat Journal of Health Sciences 4, no. 2 (2019): 684–87. http://dx.doi.org/10.3126/bjhs.v4i2.25435.
Full textAbstract:
Introduction: Lower urinary tract symptoms (LUTS) is a group of symptoms relating to stages of micturation such as storage symptoms, voiding dysfunction and post micturation dysfunction. Overactive bladder symptom score (OABSS) is a questionnaires with scores which helps in evaluating the severity of symptoms.
 Objectives To find the incidence of women visiting with LUTS and to evaluate storage symptoms in LUTS (urgency, urge incontinence, frequency) using OABSS (overactive bladder symptom score) questionnaires.
 Methodology This is a prospective study done from February 2016 to February 2017. Patients visiting Department of Obstetrics and Gynaecology with lower urinary tract symptoms (LUTS) were enrolled in the study after informed consent. Patients were assessed for types of LUTS and data were filled in the performa. If patients had urgency, urge incontinence, increased day time frequency, then the patients were explained and asked overactive bladder symptom score questionnaire (OABSS) and noted. Patients were then examined for pelvic floor dysfunction and neurological abnormalities for identifying association with the symptoms. Statistical analysis was done using SPSS 11.5.
 Results Fifty-seven patients were enrolled with lower urinary tract symptoms (LUTS) during study period. Forty-six patients had overactive bladder symptoms (OABS). LUTS were found in age ranging from 21 to 80 years. Majority of patients visiting out-patient department with LUTS were found to have urgency, urge incontinence, increased day time frequency, nocturia. Patients with urgency and urge incontinence showed significant correlation with increasing likert score of OABSS (p<0.05). But the increased day time frequency did not show any correlation with increasing score. The score showed significant correlation with combination of symptoms (urgency, urge incontinence and increased frequency) than patients presenting with single symptom.
 Conclusion Diagnosis of LUTS with valid assessment tools and treatment benefits patients with chronic urinary symptoms and also helps clinicians to further re-assess the treatment.
18
Thiagarajan, Senthil Kumar, Vikrant Mahajan, Jambunathan Saravanan, et al. "A Comparative Study of Efficacy and Tolerability of Solifenacin and Mirabegron, for the Treatment of Overactive Bladder - A Randomized Prospective Control Study." Journal of Evolution of Medical and Dental Sciences 10, no. 42 (2021): 3654–58. http://dx.doi.org/10.14260/jemds/2021/741.
Full textAbstract:
BACKGROUND Overactive bladder (OAB) is a chronic, age-related disorder seen in 11 % of patients. Symptoms consist of urinary urgency, with or without urinary incontinence, usually with frequency or nocturia. The objective of the present study was to compare the efficacy and side effects of mirabegron and solifenacin as primary therapies in patients with overactive bladder. METHODS This was a prospective interventional study. 100 patients aged between 18 years and 50 years with overactive bladder were included and were assigned into two treatment groups of solifenacin 5 mg or mirabegron 50 mg. They were asked to record the number of micturitions in a day, urgency episodes, incontinence episodes and volume of each micturition. All patients went through a basic workup with blood sugar to rule out diabetes, USG KUB to rule out bladder stones, and urine culture and sensitivity to rule out urinary tract infection (UTI). RESULTS 100 patients with OAB were selected for the study and divided into equal groups, 50 receiving 5 mg solifenacin and 50 receiving 50 mg mirabegron. Both groups increased the mean micturition volume but mirabegron was more effective in increasing the mean micturition in patients with OAB. Both drugs were well tolerated. There was a significant increase in mean micturition volume in mirabegron 50 mg group (by 20.7 + / - 2.2 mL), P < 0.001 whereas in solifenacin group micturition volume was increased to 22.2 + / -0.97 ml). The most common side-effect in the mirabegron group was hypertension and the most common side effect in the solifenacin group was dry mouth. CONCLUSIONS Both mirabegron and solifenacin were effective in controlling the frequency of micturition, decreasing urgency and incontinence episodes and increasing the mean volume of micturition. Mirabegron was more effective than solifenacin in controlling urgency and incontinence episodes and increasing the mean volume of micturition. KEY WORDS Overactive Bladder (OAB), Micturition, Mirabegron, Solifenacin.
19
Wiatr, Tomasz, and Piotr Chłosta. "Long-term clinical use of mirabegron in patients with overactive bladder syndrome." Medycyna Faktów 13, no. 4 (2020): 460–64. http://dx.doi.org/10.24292/01.mf.0420.12.
Full textAbstract:
Overactive bladder syndrome (OAB) is defined by the International Continence Society (ICS) as urinary urgency with increased daytime frequency and nocturia in the absence of proven infection or any other pathology, usually with or without urgency incontinence. Pharmacotherapy with antimuscarinic drugs is highly effective, but more than 60% of patients discontinue the treatment. Development of mirabegron, a β3-adrenoceptor agonist (β3-AR), has become an expected pharmacotherapy option for the non-invasive treatment of overactive bladder. The available studies show that long-term treatment with 50 mg mirabegron in patients with OAB is associated with reducing the severity of symptoms. Data from clinical trials show that mirabegron provides efficacy similar to antimuscarinic drugs, but with a better tolerance profile.
20
Mirzayeva, Nurlana, Susanne Forst, Daniel Passweg, Verena Geissbühler, Ana Paula Simões-Wüst, and Cornelia Betschart. "Bryophyllum pinnatum and Improvement of Nocturia and Sleep Quality in Women: A Multicentre, Nonrandomised Prospective Trial." Evidence-Based Complementary and Alternative Medicine 2023 (February 7, 2023): 1–8. http://dx.doi.org/10.1155/2023/2115335.
Full textAbstract:
Nocturia is a pathologic condition that significantly affects the quality of sleep. The aetiology of nocturia is multifactorial, and the evidence available on its management remains limited. Besides behavioural measures, validated pharmaceutical treatment options exist but are, however, associated with marked side effects. Prospective clinical studies with tablets prepared from the leaf press juice of the plant Bryophyllum pinnatum revealed a tendency towards reduction of micturition in patients with overactive bladder (OAB) and several improvements in sleep quality. These observations are in part supported by in vitro and in vivo data. In the present study, we investigated the effectiveness of Bryophyllum 50% chewable tablets in the treatment of nocturia and associated sleep disorders. Altogether, 49 women with idiopathic OAB and nocturia of ≥2 voids/night were treated with Bryophyllum 50% tablets for 3 weeks (350 mg chewable tablets, dosage 0-0-2-2 oral tablets; WELEDA AG, Arlesheim, Switzerland). Nocturia, voiding volumes at night (ml), quality of life, sleep quality, and daily sleepiness were assessed before and after treatment with a 3-day micturition diary, the International Consultation on Incontinence evaluating overactive bladder and related impact on quality of life (QoL) [ICIQ-OAB], the Pittsburgh Sleep Quality Index (PSQI), and the Epworth Sleepiness Scale (ESS), respectively. The age of the study population was 68.5 ± 11.6 y. After treatment, nocturia diminished from 3.2 ± 1.4 to 2.3 ± 1.3 ( P < 0.001 ) and the PSQI score decreased from 7.7 ± 3.7 to 6.6 ± 3.4 ( P = 0.004 ). Urgency, the ICIQ score, and the ESS lowered significantly, and the micturition volume showed a tendency to increase. No serious adverse drug reactions were reported, and compliance was good. The results show a beneficial effect on the nocturnal voids and sleep quality of women with OAB. Bryophyllum 50% tablets can be regarded as a well-tolerated alternative in the treatment of nocturia and broaden the repertoire of standard management.
21
Sooknarine, Celine, Sylvia Farrell, Susmita Sarma, et al. "Pilot Study of a Digital Behavioral Therapy for Overactive Bladder in Women." Obstetrical & Gynecological Survey 80, no. 3 (2025): 159–60. https://doi.org/10.1097/ogx.0000000000001383.
Full textAbstract:
(Abstracted from Urogynecology (Phila) 2024) Overactive bladder (OAB) is associated with urgency urinary incontinence, urinary frequency, and nocturia and is defined by symptoms of urgency that cannot be postponed; it occurs in as many as 1 in 6 adults, with a higher prevalence in women and elderly individuals, and can significantly impact quality of life. Current guidelines surrounding treatment of OAB recommend behavioral therapy (BT) first, then pharmaceuticals, then invasive treatments in a tiered approach.
22
Astuti, Vitaria Wahyu, Ayu Ratantri, and Sandy Kurniajati. "Literature Review: Quality of Life in Patients with Overactive Bladder." Jurnal Ners dan Kebidanan (Journal of Ners and Midwifery) 9, no. 1 (2022): 127–34. http://dx.doi.org/10.26699/jnk.v9i1.art.p127-134.
Full textAbstract:
Overactive Bladder, hereinafter referred to as OAB, is a complaint of urgency accompanied by urgency incontinence or without urgency incontinence, which is usually followed by an increase in urinary frequency during the day and nocturia, without infection or other pathology of the bladder. OAB can affect the quality of life of sufferers. This study analyzes the relationship between OAB and quality of life based on databases such as Science Direct, Elsevier, Willey Library, Sage Journal, and Google Scholar, 2010-2020. The study results show that the prevalence of OAB in men and women increases with age and women are at greater risk major have OAB. The incidence of OAB is most experienced at the age of > 60 years. Based on 10 journals, 6 journals stated that there was a relationship between OAB and quality of life. The conclusion of this study is that OAB can reduce the quality of life in men and women
23
Duncan, Debbie. "Role of the community nurse in Parkinson's disease and lower urinary disorders." British Journal of Community Nursing 26, no. 5 (2021): 251–54. http://dx.doi.org/10.12968/bjcn.2021.26.5.251.
Full textAbstract:
Parkinson's disease (PD) is an incurable and progressive neurodegenerative disorder. People with PD also have increased muscle weakness and the typical symptoms of tremor, stiffness, slowness, balance problems and/or gait disorders. Other symptoms may include an overactive bladder, urgency and nocturia which can often lead to incontinence. Treatment options vary are dependent on the cause of the incontinence and should focus on improving Quality of life with a multi-pronged diagnosis-specific approach that takes into consideration a patient's ability to comply with treatment. The article looks at the role of the community nurse in caring for patients with PD and lower urinary disorders. They have a key role in assessment of patients and supporting families with tailor made bladder training such as establish a regular toilet routine, education about pelvic floor exercises or supply of incontinence products.
24
Palma, Thais, Raimondi Marina, Souto Sophia, Fozzatti Celina, Palma Paulo, and Riccetto Cassio. "Correlation between body mass index and overactive bladder symptoms in pre-menopausal women." Revista da Associação Médica Brasileira 60, no. 2 (2014): 111–17. http://dx.doi.org/10.1590/1806-9282.60.02.007.
Full textAbstract:
Objective: The aim of the study was to establish a correlation between Overactive Bladder (OAB) symptoms and Body Mass Index (BMI) in women aged 20-45. Methods: We interviewed 1.050 women aged 20-45 in the area of Campinas, Brazil, to investigate the prevalence of overactive bladder symptoms. In this study, we used the ICIQ-OAB questionnaire (ICS standard), in its validated portuguese version and a specific questionnaire for the demographics, which includes information about BMI. Results: Overall, women with BMI ≥30 presented a significantly higher score than women with a lower BMI (18.5 - 24.9) (p=0.0066). In the analysis of individual symptoms, no significant differences were found regarding urinary frequency (p=0.5469). Women with BMI ≥30 presented more nocturia than women with BMI ranging between 18.5 and 24.9 (p=0.0154). Women in the group of BMI 25 - 29.9 presented more urgency than women with BMI 18.5 - 24.9 (p=0.0278). Significant difference was also found regarding urge-incontinence; women with BMI 25 - 29.9 presented a higher score than women in the group 18.5 - 24.9 (p= 0.0017). Analysis was also performed on the visual analogue scale regarding how much each symptom bothers the women (quality of life). There were no significant differences regarding frequency, nocturia or urgency but urgency incontinence bother was significant. Women with BMI 25 - 29.9 were more bothered by incontinence than women with BMI 18.5 - 24.9 (p=0.002). Conclusion: In conclusion, this study reinforces the correlation between BMI and OAB symptoms. Obese women present more OAB symptoms than non-obese women.
25
Carpenter, Lucy, and Nicholas J. Campain. "Overactive bladder: not just a normal part of getting older." British Journal of Nursing 31, no. 18 (2022): S16—S22. http://dx.doi.org/10.12968/bjon.2022.31.18.s16.
Full textAbstract:
Overactive bladder (OAB) is a common yet under-reported condition affecting both men and women. Prevalence rises with age, but OAB can affect people of any age. It is associated with increased physical and mental health problems and may lead to social isolation and escalating care needs. It is a clinical diagnosis with symptoms of urgency, with or without urge incontinence and usually with urinary frequency and nocturia. Management includes conservative, medical and surgical treatments, which can significantly improve quality of life. This review aims to raise awareness of this under-reported condition and to empower health professionals to open discussions on bladder health with all those in their care.
26
Fontaine, Christina, Emma Papworth, John Pascoe, and Hashim Hashim. "Update on the management of overactive bladder." Therapeutic Advances in Urology 13 (January 2021): 175628722110390. http://dx.doi.org/10.1177/17562872211039034.
Full textAbstract:
Overactive bladder (OAB) syndrome is a common condition characterised by urinary urgency, with or without urgency incontinence, frequency and nocturia, in the absence of any other pathology. Clinical diagnosis is based upon patient self-reported symptomology. Currently there is a plethora of treatments available for the management of OAB. Clinical guidelines suggest treatment via a multidisciplinary pathway including behavioural therapy and pharmacotherapy, which can be commenced in primary care, with referral to specialist services in those patients refractory to these treatments. Intradetrusor botulinum A and sacral neuromodulation provide safe and efficacious management of refractory OAB. Percutaneous tibial nerve stimulation and augmentation cystoplasty remain available and efficacious in a select group of patients. Unfortunately, there remains a high rate of patient dissatisfaction and discontinuation in all treatments and thus there remains a need for emerging therapies in the management of OAB.
27
Ananda, I. Gede Yogi Prema, Radika Naufal Hadi Surya, Prima Ardiansah Surya, Alfin Putratama, and Dimas Panca Andhika. "Efficacy and safety of solifenacin for overactive bladder: An updated systematic review and meta-analysis." Urology Annals 17, no. 1 (2025): 2–8. https://doi.org/10.4103/ua.ua_30_24.
Full textAbstract:
Overactive bladder (OAB) is a chronic disease with the symptoms of urgency with or without incontinence. Solifenacin is an antimuscarinic drug that Excels in OAB treatment due to its specific bladder receptor targeting. While previous research had positive outcomes, reports of adverse events (AEs) highlight the need for regular updates on the safety and efficacy of solifenacin for OAB management. This study followed PRISMA 2020 guidelines and was registered to PROSPERO CRD42023445318. A comprehensive search of PubMed, ScienceDirect, and Scopus databases was conducted until July 2023. Data were analyzed using Review Manager version 5.4 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). Solifenacin had a significantly better effect in decreasing urgency episode (mean difference (MD) = −1.09, 95% confidence interval [CI]: −1.29–−0.89, P < 0.00001), incontinence episode (MD = −0.56, 95% CI: −0.80–−0.32, P < 0.00001), micturition frequency (MD = −1.01, 95% CI: −1.16–−0.85, P < 0.00001), nocturia episode (MD = −0.13, 95% CI: −0.25–−0.01, P = 0.04), and had a higher urine volume (MD = 26.88, 95% CI: 24.17–29.59, P < 0.00001) per 24 h compared to placebo. Solifenacin had a significant number of AEs compared to placebo (MD = 1.75, 95% CI: 1.25–2.45, P = 0.001). Solifenacin significantly decreased urgency episode, incontinence episodes, micturition frequency, and nocturia episode, and had a higher urine volume per 24 h. There was a significant number of AEs in patients receiving solifenacin.
28
Mansfield, Kylie J. "Muscarinic Receptor Antagonists, the Overactive Bladder and Efficacy against Urinary Urgency." Clinical Medicine Insights: Therapeutics 2 (January 2010): CMT.S4606. http://dx.doi.org/10.4137/cmt.s4606.
Full textAbstract:
The overactive bladder (OAB) is a debilitating condition in which patients suffer from urinary urgency, frequency and nocturia with or without urge urinary incontinence. The mainstay of pharmacotherapy for OAB is muscarinic receptor antagonists, which have been shown to be effective treatments for the symptoms of OAB. The mechanism underlying the efficacy of antimuscarinic agents against the symptoms of OAB is not completely understood. This review explores the role of bladder mucosal muscarinic receptors in the signaling pathways that are activated in response to bladder filling. The cholinergic system is seen to be involved in bladder afferent signaling at many levels and as such muscarinic receptor antagonists may affect bladder signaling via numerous pathways including release of mediators from the bladder urothelium and activation of suburothelial myofibroblasts and afferent nerves. Therefore the mucosal cholinergic system may represent another target for the antimuscarinic agents used to treat OAB.
29
Allison, Sara J., and William Gibson. "Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience." Therapeutic Advances in Urology 10, no. 12 (2018): 411–19. http://dx.doi.org/10.1177/1756287218801282.
Full textAbstract:
Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other pathology, is a common, distressing and often debilitating condition with a high prevalence in the general population. For many years, the only available pharmacological treatment for OAB were the antimuscarinic agents. More recently, mirabegron, a selective agonist of the β3 adrenergic receptor, has become available. In this article we review the current evidence and experience of its use.
30
Fitz, Fátima, Marair Sartori, Manoel João Girão, and Rodrigo Castro. "Pelvic floor muscle training for overactive bladder symptoms – A prospective study." Revista da Associação Médica Brasileira 63, no. 12 (2017): 1032–38. http://dx.doi.org/10.1590/1806-9282.63.12.1032.
Full textAbstract:
Summary Introduction: Pelvic floor muscle training (PFMT) involves the contraction of the puborectal, anal sphincter and external urethral muscles, inhibiting the detrusor contraction, what justify its use in the treatment of overactive bladder (OAB) symptoms. Objective: To verify the effects of isolated PFMT on the symptoms of OAB. Method: Prospective clinical trial with 27 women with mixed urinary incontinence (MUI), with predominance of OAB symptoms and loss ≥ 2 g in the pad test. It was evaluated: pelvic floor muscles (PFMs) function (digital palpation and manometry); urinary symptoms (nocturia, frequency and urinary loss); degree of discomfort of OAB symptoms; and quality of life (Incontinence Quality-of-Life Questionnaire [I-QoL]). The PFMT program consisted of 24 outpatient sessions (2x/week + home PFMT). The Mann-Whitney and Wilcoxon tests (with a significance level of 5%) were used to analyse the data. Results: There was a significant improvement of the urinary symptoms to the pad test (5.8±9.7, p<0.001), urinary loss (0.7±1.1, p=0.005) and nocturia (0.8±0.9, p=0.011). Reduction in the degree of discomfort of urinary symptoms was observed according to OAB-V8 questionnaire (10.0±7.7, p=0.001). There were also significant results in PFMs function: Oxford (3.6±0.9, p=0.001), endurance (5.2±1.8, p<0.001), fast (8.9±1.5, p<0.001) and manometry (26.6±15.8, p=0.003). In addition, quality of life had a significant improvement in the three domains evaluated by I-QoL. Conclusion: The PFMT without any additional guidelines improves the symptomatology, the function of PFMs and the quality of life of women with OAB symptoms.
31
Wiatr, Tomasz, and Piotr Chłosta. "Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder." Medycyna Faktów 14, no. 1 (2021): 53–57. http://dx.doi.org/10.24292/01.mf.0121.6.
Full textAbstract:
Lower urinary tract symptoms, including urgency, urgency incontinence, pollakiuria and nocturia are common in the elderly people and has significant impact on quality of life. Pharmacological treatment is recommended when conservative management, such as fluid intake normalization or bladder training, does not alleviate symptoms. Antimuscarinics were often used as the I line treatment for OAB, as these drugs block the activity of the muscarinic M2/M3 receptors in the bladder and provide a significant clinical benefit for OAB symptoms in the elderly people, but their side effects are common, often leading to treatment discontinuation. Mirabegron, a β3-adrenoceptor agonist, shows similar efficacy to antimuscarinic drugs without the risk of anticholinergic effects.
32
Hakimi, Sevil, Sakineh Hajebrahimi, Marzieh Mohammadi, Elham Aminian, and Samieh Ghana. "207: TRANSLATION AND PSYCHOMETRIC PROPERTIES OF IRANIAN VERSION OF OVERACTIVE BLADDER SYNDROME SCORE (OABSS)." BMJ Open 7, Suppl 1 (2017): bmjopen—2016–015415.207. http://dx.doi.org/10.1136/bmjopen-2016-015415.207.
Full textAbstract:
Background and aims:Overactive bladder (OAB) especially OAB with incontinence, influences an individual's lifestyle behavior and impairs quality of life and interfere with daily activities. Since the OAB is diagnosed based on subjective symptoms, the patients reports, is used in the assessment and management of patients with OAB. Therefore it needs to assess the severity of OAB and evaluate the treatment outcome with an objective diagnostic tool. Overactive Bladder Symptom Score (OABSS) is appropriate tool because it can survey all complexities of OAB symptoms and has a graded response for severity score. The aim of this study is assessment of translation and validity of Persian version of OABSS questionnaire.Methods:One hundred, menopausal women aged 45 years or older who had at least one urgency episode with or without urge incontinence in the last 3 days, lasting at least 3 months were recruited at the outpatient gynecology clinics of 2 university affiliated hospitals in Tabriz. Patients were excluded if they had significant stress incontinence or mixed stress/urge incontinence where stress was the predominant factor, indwelling catheter, urinary tract infection, and pharmaceutical or non-pharmaceutical treatment for OAB during last 4 weeks.For confirmation OAB, all of participants were asked and directed to completed bladder diary, 3 days before the first visit. To determine diagnosis of urinary tract infection, a urine analysis was taken from each participant at the same time. Patients excluded if they could not complete correctly their 3-day urinary diary at visit 1 (Week0) according to the instructions or had bacteriuria/pyuria. The diary was recorded episodes of urgency, incontinence, nocturia and number of incontinence pads.All eligible patients completed a socio- demographic questionnaire, Three- day bladder diary, Persian version of OABSS and International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) at the first visit (week 0) Then, subjects were instructed to attend the retest visit approximately 14±2 days after the first visit where the same questionnaires (except of socio demographic questionnaire) were documented.The translation and adaptation process was conducted with using forward- backward translation approach. For evaluation construct validity, we used of convergent validity with using of ICIQ-OAB Persian version. For measuring reliability test re-test reliability was calculated. Internal consistency was evaluated by measuring Cronbach Alpha.Results:This study was performed between Aprils to July 2016. Out of 274 patients who were evaluated, 100 were recruited in the study. One hundred twenty four individuals had not inclusion criteria and 30 participants did not complete the first diary. The mean (SD) age of participants was 54.3 (4.0) and 89% of participants were housewife. Cronbach alpha coefficient for OABSS was 0.79.Conclusion:The results of this study was demonstrated that Persian version of OABSS has acceptable validity and reliability.Table 1The results of convergent validity with ICIQ and test re-test reliability were summarizedOABSSTest retest reliabilityN=30Convergent validityN=100Item 1 (frequency)0.780.83Item2 (nocturia)0.810.84Item3 (urgency)0.700.79Item4 (urgency/incontinence)0.730.71
33
Ramos, Marta L., Carmen García-Cabo, Rogelio Leira, et al. "Comorbidity between idiopathic overactive bladder and chronic migraine." Cephalalgia 38, no. 3 (2017): 581–84. http://dx.doi.org/10.1177/0333102417690127.
Full textAbstract:
Objective We tested whether overactive bladder (OAB) and chronic migraine (CM) could be comorbid. Patients and methods CM women, aged 40–69 years, answered a validated OAB questionnaire. Prevalence data were compared with those reported in our country in the general population (GP) using the same questionnaire. Results We interviewed 231 CM women. Eighty-four met OAB criteria. OAB prevalence in CM patients was significantly higher than that found in the GP (36.4% vs. 21.8% in the GP; p = 0.0001). There were 34 CM women aged 40–49 years (34.3% vs. 15.2%; p = 0.001), 35 aged 50–59 years (38.9% vs. 21.7%; p = 0.004) and 15 aged 60–69 years (35.7% vs. 24.5%; p = 0.15) meeting OAB criteria. Seventy-seven (33% vs. 9.9%; p = 0.002) needed more than eight micturitions/24 h, 61 (26.4% vs. 8.1%, p = 0.002) experienced nocturia and 43 (18.6% vs. 8.1%; p = 0.001) urinary incontinence. Conclusion In this exploratory study, at least in women, OAB and CM are comorbid, which suggests shared mechanisms.
34
Yoon, Hana. "Chronic bladder diseases: overactive bladder and interstitial cystitis/bladder pain syndrome." Journal of the Korean Medical Association 64, no. 11 (2021): 763–69. http://dx.doi.org/10.5124/jkma.2021.64.11.763.
Full textAbstract:
Background: Overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome (IC/BPS) are debilitatingchronic bladder diseases that affect patients’ quality of life. Their etiologies and clinical phenotypes vary, and management strategies should be selected after excluding the possibilities of other pathological conditions with careful consideration of a multidisciplinary integrated approach to ensure optimal success.Current Concepts: OAB is a symptom complex characterized by urinary urgency and frequency and nocturia with or without urge incontinence, and its key symptom is urinary urgency. IC/BPS has symptoms similar to lower urinary tract symptoms (LUTS) associated with OAB but also has distinctly different symptoms, including the key symptom of an unpleasant sensation or pain perceived to be related to the urinary bladder associated with LUTS. Recent studies have revealed that these key symptoms of OAB or IC/BPS are also observed in some patients with other diseases. Patients showing no evidence of bacterial infection on urine culture and experiencing LUTS or pain for more than 6 weeks should be considered as having OAB or IC/BPS. Treatment strategies for OAB and IC/BPS focus on managing LUTS and bothersome pain. Noninvasive management should be considered initially, whereas surgical options should be considered only after conservative treatment failure.Discussion and Conclusion: OAB and IC/BPS symptoms overlap considerably in many patients. A more accurate differentiation of symptoms, including LUTS, would help achieve better treatment outcomes.
35
Krivoborodov, G. G., O. N. Tkacheva, N. S. Efremov, D. A. Shyrin, and A. A. Gontar. "Trospium chloride in older patients with idiopathic overactive urinary badder." Russian Journal of Geriatric Medicine, no. 1 (May 25, 2022): 58–63. http://dx.doi.org/10.37586/2686-8636-1-2022-58-63.
Full textAbstract:
Overactive bladder (OAB) — is a clinical syndrome which includes urge urination with or without urge urinary incontinence which is usually accompanied by frequent urination and nocturia. In most cases, OAB does not pose a threat to the life of patients, but significantly worsens the quality of all spheres of human life. Urge urinary incontinence is one of the main causes of falls in older patients, which often leads to fractures of the proximal femur and is accompanied by severe complications. Drug therapy with M-cholinoblockers (cholinolytics) is the leading direction in the treatment of patients with OAB. However, this type of therapy remains poorly understood in older men and women. The choice of an effective and safe cholinolytic for older and senile patients is the subject of discussion and scientific research. The results obtained show trospium chloride as an effective drug for the treatment of urgent and frequent urination due to idiopathic OAB, as well as the lack of influence on cognitive function in older patients.
36
Dhani, Fauzan Kurniawan, and Wendi Rachman. "Efficacy and Safety of Combination therapy compared to Monotherapy for Overactive Bladder: A Meta-Analysis." Brawijaya Journal of Urology 3, no. 02 (2023): 39–49. http://dx.doi.org/10.11594/bjurology.2023.003.02.4.
Full textAbstract:
Introduction. Overactive Bladder (OAB) Syndrome is urinary urgency often accompanied by increased daytime frequency and nocturia, with or without urgency incontinence. Individuals with OAB report significant impairment to quality of life. Antimuscarinic become first line therapy of OAB patients with dose escalation or change of antimuscarinic if symptom improvement is inadequate. Increasing the antimuscarinic dose often exacerbates anticholinergic Adverse Events (AEs) that can lead to treatment discontinuation. The aim of this meta-analysis to find out the efficacy and safety of combination therapy compared to solifenacin alone.Methods . We searched for data’s of Randomized clinical trials in PUBMED, EMBASE, and the Cochrane Library. There was no year restriction and only English is allowed. The outcomes were Micturition Episode/24h , Incontinence Episode/24h , AEs and Discontinue medication due to AEs. The data’s were carried out using PRISMA guideline and statistically analysed by using RevMan 5.3.0.Result. Three RCTs studies, including 7007 patients were assessed for efficacy and safety of combination therapy compared solifenacin alone. It is revealed Micturation [HR -0.46; 95%CI: -0.63, -0.29; I2 13%; p<0.00], Incontinence [HR -0.27; 95%CI: -0.42, -0.13; I2 13%; p<0.00], Adverse Events [HR 1.09; 95%CI: 0.94, 1.27; I2 0%; p=0.27] and Discontinue Medication due to AEs [HR 1.26; 95%CI: 0.70, 2.24; I2 0%; p=0.44].Conclusion. The efficacy of combination therapy of mirabegron plus solifenacin significantly improved storage symptoms regarding micturition and incontinence episode, compared to solifenacin monotherapy. Combination therapy provides better therapeutic benefits for patients with overactive bladder syndrome.
37
Rodrigues, Rafaela Fintelman, and Elirez Bezerra da Silva. "Intracavitary electrical stimulation as treatment for overactive bladder: systematic review." Fisioterapia em Movimento 29, no. 4 (2016): 813–20. http://dx.doi.org/10.1590/1980-5918.029.004.ao18.
Full textAbstract:
Abstract Introduction: Overactive bladder (OAB) is a clinical diagnosis of irritating urinary symptoms that influence on sufferers' life quality. There are effective treatments described in literature, but most of them present adverse effects. One way of treatment is the use of electrical stimulation, which has been widely used, but studies show varying results. Objective: To verify if intracavitary electrical stimulation can be effective in patients with OAB. Methods: online databases were searched with specific descriptors to find randomized clinical trials on overactive bladder treated with intracavitary electrical stimulation. Only articles with score equal or higher than 5 in methodological PEDro scale were used and those that described intra and / or inter-group P-value. Results: 217 articles were found, but only 6 were analyzed by the selection criteria. The studies show that electrical stimulation promotes the reduction of urinary frequency, urinary incontinence, nocturia, urgency and the number of protectors used, and improvements in maximum cystometric bladder capacity, symptoms of OAB and quality of life. Conclusion: Electrical stimulation was effective in patients with OAB and can be used before any invasive treatment due to none side effects.
38
Moratalla Charcos, Luz María, Jorge Planelles Gómez, Belén García Mora, Cristina Santamaría Navarro, and Juan Francisco Vidal Moreno. "Efficacy and satisfaction with transcutaneous electrostimulation of the posterior tibial nerve in overactive bladder syndrome." Journal of Clinical Urology 11, no. 5 (2018): 331–38. http://dx.doi.org/10.1177/2051415818776186.
Full textAbstract:
Objective: Overactive bladder is a disease with a high prevalence. The management is difficult, because different demographic, social or economic aspects converge. Our objective was to evaluate the efficacy and satisfaction in patients with overactive bladder treated with transcutaneous electrostimulation of the posterior tibial nerve. Methods: This was a prospective and descriptive study of 45 patients with overactive bladder (with or without detrusor overactivity) resistant to pharmacological treatment. Patients received a weekly session for 12 weeks, with a duration of 30 minutes for each of the sessions. There was a screening after 12 sessions, after which if there had been no response, treatment was suspended and maintenance sessions were not continued (six twice-monthly sessions and three monthly sessions). It was considered that the treatment had been effective when it was possible to decrease the number of events, except the maximum voiding volume, the objective of which was to increase. The results were evaluated using a 3-day voiding diary, an overactive bladder short form questionnaire and a satisfaction level questionnaire. Statistical analysis was performed using IBM SPSS Statistics version 19.0. Independent variables with a normal distribution were examined using the t-test. The Wilcoxon signed-rank test was used to compare the averages of the quantitative variables without a normal distribution. Satisfaction was analysed by a binary and ordinal regression analysis, univariate and multivariate. A P value less than 0.05 was considered statistically significant. Results: All the parameters of the study improved to a statistically relevant degree: frequency, nocturia, urgency, maximum voided volume, urge urinary incontinence. The overactive bladder short form questionnaire score improved but was not statistically significant. Conclusions: The use of transcutaneous electrostimulation of the posterior tibial nerve is a safe, effective and minimally invasive alternative in the treatment of overactive bladder when pharmacological treatment has failed. Patients had a good objective and subjective response in our study. Level of evidence: 4.
39
SEERWAN, M., M. ADNAN, H. SHAFI, N. JAVED, M. ILYAS, and M. HUSSAIN. "THE SAFETY AND EFFICACY OF SOLIFENACIN AS COMPARED TO MIRABEGRON IN OVERACTIVE BLADDER SYNDROME PATIENTS IN THE ADULT POPULATION OF DERA ISMAIL KHAN." Biological and Clinical Sciences Research Journal 2023, no. 1 (2023): 239. http://dx.doi.org/10.54112/bcsrj.v2023i1.239.
Full textAbstract:
An overactive bladder syndrome is a group of symptoms, i.e., frequency, urgency, nocturia, and sometimes accompanied by urge incontinence. The recent pharmacological options are some drugs, mainly used anti-muscarinic. However, anti-muscarinic drugs have different adverse effects, i.e., constipation and dry mouth. In 2011, a β3 receptor agonist, mirabegron, was studied to treat overactive bladder syndrome. This non-randomized trial was conducted in the Department of Urology, Gomal medical college, D.I. Khan, KPK Pakistan. The study was done from June 2018 to January 2022. We divided 4220 patients into two equal groups. Group a used solifenacin 5 mg for 6 weeks, while group B used mirabegron 50 mg for the same duration. We assessed safety and efficacy after 6 weeks. Most of the adverse effects were mild to moderate severity. Dry mouth occurred in 125 patients out of 2110 (5.92%) in group A and 66 out of 2110 (3.12%) in group B. p-value = 0.0001. Constipation occurred in 53 (2.51%) patients in group A and 46 (2.18%) patients in group B. p-value=0.5417. The improvement in overactive bladder symptoms score (OBSS) occurred in 1443 out of 2110 (68.38%) patients in group A and 1409 out of 2110 (66.77%) patients in group B. p-value=0.2778. Based on the results, it can be concluded that Mirabegron has fewer adverse effects than solifenacin, while both drugs are approximately similar in efficacy.
40
Govier, Fred E., Neila Smith, and Takeshi Uchida. "Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial." Clinical Medicine Insights: Urology 4 (January 2010): CMU.S4960. http://dx.doi.org/10.4137/cmu.s4960.
Full textAbstract:
Introduction This multicenter, randomized, double-blind, parallel-group, Phase III, pivotal trial investigated the efficacy and safety of solifenacin succinate 10 mg, a once-daily (OD) oral antimuscarinic agent, in overactive bladder syndrome (OAB). Materials and methods A total of 634 adult patients with OAB symptoms were randomized to either solifenacin 10 mg (n = 318) or placebo (n = 316) OD over 12 weeks, to examine changes from baseline in micturition-, incontinence-, urgency- and nocturia-episodes/24 hours, measured using a 3-day diary. Results Solifenacin significantly reduced the mean number of micturition-, urgency- and incontinence-episodes/24 hours at end of treatment ( P < 0.001 for all versus placebo); these improvements were observed at 4 weeks, and continued over 12 weeks. Adverse events were generally mild or moderate in severity and typically anticholinergic in nature. Conclusions Solifenacin 10 mg OD was well tolerated and effective in treating major OAB symptoms, including urinary incontinence, frequency and urgency.
41
ČERNIAUSKIENĖ, Aušra, and Feliksas JANKEVIČIUS. "Botulinum toxin therapy for nonneurogenic overactive bladder: first experience." Acta medica Lituanica 18, no. 3 (2011): 120–26. http://dx.doi.org/10.6001/actamedica.v18i3.1825.
Full textAbstract:
The paper presents early experience in the treatment of 20 patients with botulinum toxin injections into the detrusor muscle for the treatment of non-neurogenic overactive bladder (OAB) resistant to anticholinergic drugs. Background. Botulinum toxin, a presynaptic neuromuscular blocking agent, reduces the involuntary bladder contractions that cause urgency, frequency and urge incontinence. We present our early experience with Dysport® injections into the detrusor for the treatment of non–neurogenic overactive bladder (OAB) resistant to anticholinergic drugs. Materials and methods. Using intravenous anaesthesia, 20 patients (18 female and 2 male) with non-neurogenic OAB were injected with botulinum toxin A (Dysport®250 IU diluted in 4 ml normal saline) under cystoscopic visualization in 20 sites in the detrusor muscle, sparing the trigone. The urethral catheter was removed 24 hours after the procedure. Follow-up at 3 and 6 months after the injection included the Urogenital Distress Inventory UDI-6, the Incontinence Impact Questionnaire IIQ-7, clinical parameters and ultrasound measurement of bladder capacity and post-void residual urine volume. Results. All 20 patients completed questionnaires and were examined after 3 and 6 months. At the 3-month follow-up, the median daytime micturation frequency decreased from 10.4 to 4.6 times (p < 0.0001) and at the 6 months follow-up 5 times (p < 0.0001), while nocturia decreased from 4.2 to 1.3 times after 3 months (p < 0.0001) and after 6 months to 2 times (p < 0.0001). Urgency decreased from 6 to 1.5 times after 3 months (p < 0.0001) and to 2 times after 6 months (p < 0.0001), and incontinence decreased from 4.2 times to 1.5 times after 3 months (p < 0.0001) and to 2.1 times after 6 months (p < 0.0001). The median maximum bladder capacity increased from 250 to 420 ml after 3 months (p < 0.0001) and decreased to 350 ml after 6 months (p < 0.0001). The post-void median residual urine volume was 10 ml. Only one patient mentioned a post-operative obstructive voiding difficulty. Eighteen (90%) patients were satisfied with the treatment. In two patients (10%), the amelioration of symptoms lasted for one month only, and later OAB symptoms reappeared. Analysis of the UDI-6 and IIQ-7 questionnaires revealed that botulinum toxin A intradetrusor injection had decreased discomfort for patients and ameliorated their quality of life. Conclusions. Botulinum toxin A injections in the detrusor are effective for the treatment of non-neurogenic OAB. Botulinum toxin A injections are a minimally invasive therapy and offer an alternative treatment for non–neurogenic OAB dysfunction resistant to conservative treatment. The durability of the treatment effect is the objective of the further investigation. Keywords: botulinum toxin, overactive bladder, urinary incontinence
42
Hefila, Nermeen Mohamed, Tamer Mamdouh And el dayem, and Hisham Adel Elfazari. "Comparison of tolterodine and Solifancine in treatment of female with overactive bladder." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 10, no. 6 (2021): 2138. http://dx.doi.org/10.18203/2320-1770.ijrcog20212140.
Full textAbstract:
Background: OAB (overactive bladder) is primarily a neuromuscular problem in which the detrusor muscle contracts inappropriately during bladder filling (i.e., storage phase). These contractions often occur regardless of the amount of urine in the bladder. The aim of this work is to study the effect of Solifenacin in comparison to Tolterodine in treatment of females with idiopathic over active bladder.Methods: This study included 50 patients who presented between March 2020 and February2021 to the outpatients clinic at El-Shatby maternity Hospital, Alexandria university. The patients were complaining of urinary urgency usually with urinary frequency, nocturia with or without urge incontinence. All cases were divided in two groups one of them receive Solifenacin5mg twice daily and the otherreceiveTolterodine2mg twice daily.Results: Both groups showed significant decrease in frequency number per day with p value <0.001ingroup I with Solifenacin which mean statistically significant difference between two groups. When the percentage of symptoms severity were compared between both groups, group 1 showed 53% reduction in symptoms severity while group II showed 6.67% reduction which cleared significant difference statistically in group I (p=0.001). The percentage of reduction of severity of symptoms was compared between the two groups, it showed about 60%reduction in symptoms severity in group 1while in group II only 9.7% reduction. This was statistically significant with (p<0.001) in group I with Solifenacin.Conclusions: This study suggests that Solifenacin10mg/day is more effective than Tolterodine4mg/day in reducing OAB incontinence episodes.
43
Bele, Uros, Tamara Serdinšek, Evgenija Homšak, and Igor But. "The Impact of Extracorporeal Magnetic Stimulation as Addition to Mirabegron in Overactive Bladder Treatment in Women: A Single-Centre Randomized Sham-Controlled Study." Journal of Clinical Medicine 13, no. 3 (2024): 916. http://dx.doi.org/10.3390/jcm13030916.
Full textAbstract:
(1) Background: The purpose of our prospective, single-blinded, randomized, sham-controlled study was to investigate the effect of the additional extracorporeal magnetic stimulation (ExMI) to pharmacological treatment in overactive bladder syndrome (OAB) in women. (2) Methods: We recruited 56 women with OAB, who were allocated into two study groups: the active group received mirabegron 50 mg daily and a total of 16 sessions of ExMI in 8 weeks, whereas the sham group received mirabegron 50 mg daily and sham stimulation following the same treatment protocol. Treatment success was evaluated after 4 and 8 weeks. (3) Results: Both groups experienced significant reduction in daytime urinary frequency, nocturia, and number of weekly incontinence episodes after 8 weeks. There were no statistically significant differences in end-point daytime urinary frequency and nocturia between groups. However, the overall average reduction rate in weekly number of incontinence episodes was 43.7% in treatment group and 24.2% in the control group. The number of urinary incontinence episodes in the treatment and control group was reduced for 3.8 ± 11.8 vs. 2.5 ± 4.3 episodes at week 4 and additional 3.3 ± 6 vs. 0.4 ± 3.2 episodes at week 8, respectively (p = 0.013). Moreover, IIQ-7 score showed a significantly greater score reduction and patients’ evaluated improvement of symptoms was higher in the active group. (4) Conclusions: The addition of ExMI to mirabegron in OAB treatment further improves the weekly incontinence episode reduction rate and also leads to grater improvement in symptoms.
44
Hsu, Lin-Nei, Ju-Chuan Hu, Po-Yen Chen, Wei-Chia Lee, and Yao-Chi Chuang. "Metabolic Syndrome and Overactive Bladder Syndrome May Share Common Pathophysiologies." Biomedicines 10, no. 8 (2022): 1957. http://dx.doi.org/10.3390/biomedicines10081957.
Full textAbstract:
Metabolic syndrome (MetS) is defined by a group of cardiovascular risk factors, including impaired glucose tolerance, central obesity, hypertension, and dyslipidemia. Overactive bladder (OAB) syndrome consists of symptoms such as urinary urgency, frequency, and nocturia with or without urge incontinence. The high prevalences of metabolic syndrome (MetS) and overactive bladder (OAB) worldwide affect quality of life and cause profound negative impacts on the social economy. Accumulated evidence suggests that MetS might contribute to the underlying mechanisms for developing OAB, and MetS-associated OAB could be a subtype of OAB. However, how could these two syndromes interact with each other? Based on results of animal studies and observations in epidemiological studies, we summarized the common pathophysiologies existing between MetS and OAB, including autonomic and peripheral neuropathies, chronic ischemia, proinflammatory status, dysregulation of nutrient-sensing pathways (e.g., insulin resistance at the bladder mucosa and excessive succinate intake), and the probable role of dysbiosis. Since the MetS-associated OAB is a subtype of OAB with distinctive pathophysiologies, the regular and non-specific medications, such as antimuscarinics, beta-3 agonist, and botulinum toxin injection, might lead to unsatisfying results. Understanding the pathophysiologies of MetS-associated OAB might benefit future studies exploring novel biomarkers for diagnosis and therapeutic targets on both MetS and OAB.
45
Rakowska-Silska, Magda, Katarzyna Jobs, Aleksandra Paturej, and Bolesław Kalicki. "Voiding Disorders in Pediatrician’s Practice." Clinical Medicine Insights: Pediatrics 14 (January 2020): 117955652097503. http://dx.doi.org/10.1177/1179556520975035.
Full textAbstract:
Voiding disorders result usually from functional disturbance. However, relevant organic diseases must be excluded prior to diagnosis of functional disorders. Additional tests, such as urinalysis or abdominal ultrasound are required. Further diagnostics is necessary in the presence of alarm symptoms, such as secondary nocturnal enuresis, weak or intermittent urine flow, systemic symptoms, glucosuria, proteinuria, leukocyturia, erythrocyturia, skin lesions in the lumbar region, altered sensations in the perineum. Functional micturition disorders were thoroughly described in 2006, and revised in 2015 by ICCS (International Children’s Continence Society) and are divided into storage symptoms (increased and decreased voiding frequency, incontinence, urgency, nocturia), voiding symptoms hesitancy, straining, weak stream, intermittency, dysuria), and symptoms that cannot be assigned to any of the above groups (voiding postponement, holding maneuvers, feeling of incomplete emptying, urinary retention, post micturition dribble, spraying of the urinary stream). Functional voiding disorders are frequently associated with constipation. Bladder and bowel dysfunction (BBD) is diagnosed when lower urinary tract symptoms are accompanied by problems with defecation. Monosymptomatic enuresis is the most common voiding disorder encountered by pediatricians. It is diagnosed in children older than 5 years without any other lower urinary tract symptoms. Other types of voiding disorders such as: non-monosymptomatic enuresis, overactive and underactive bladder, voiding postponement, bladder outlet obstruction, stress or giggle incontinence, urethrovaginal reflux usually require specialized diagnostics and therapy. Treatment of all types of functional voiding disorders is based on non-pharmacological recommendations (urotherapy), and such education should be implemented by primary care pediatricians.
46
Bapir, Rawa, Kamran Hassan Bhatti, Ahmed Eliwa, et al. "Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials." Archivio Italiano di Urologia e Andrologia 94, no. 4 (2022): 492–506. http://dx.doi.org/10.4081/aiua.2022.4.492.
Full textAbstract:
Background: Overactive bladder (OAB) symptoms of frequency, urgency and urge incontinence are frequently associated with known neurological diseases like multiple sclerosis (MS), spinal cord injury (SCI), Parkinson’s disease (PD), stroke. Objective: The aim of our study was to review the efficacy of pharmacological and non-pharmacological treatments for neurogenic overactive bladder. Materials and methods: We searched two electronic databases (PubMed and EMBASE) for randomized controlled trials focusing on pharmacological and non-pharmacological medical treatments for overactive bladder symptoms associated with neurological diseases published up to 30 April 2022. Results: A total of 157 articles were retrieved; 94 were selected by title and abstract screening; after removal of 17 duplicates, 77 records were evaluated by full-text examination. Sixty-two studies were finally selected. The articles selected for review focused on the following interventions: anticholinergics (n = 9), mirabegron (n = 5), comparison of different drugs (n = 3), cannabinoids (n = 2), intravesical instillations (n = 3), botulinum toxin (n = 16), transcutaneous tibial nerve stimulation (TTNS) (n = 6), acupuncture (n = 2), transcutaneous electrical nerve stimulation TENS (n = 4), pelvic floor muscle training (PFMT) (n = 10), others (n = 2). Anticholinergics were more effective than placebo in decreasing the number of daily voids in patients with PD (mean difference [MD]- 1.16, 95 % CI - 1.80 to - 0.52, 2 trials, 86 patients, p < 0.004), but no significant difference from baseline was found for incontinence episodes and nocturia. Mirabegron was more effective than placebo in increasing the cystometric capacity in patients with MS (mean difference [MD] 89.89 mL, 95 % CI 29.76 to 150.01, 2 trials, 98 patients, p < 0.003) but no significant difference was observed for symptom scores and bladder diary parameters. TTNS was more effective than its sham-control in decreasing the number of nocturia episodes (MD -1.40, 95 % CI -2.39 to -0.42, 2 trials, 53 patients, p < 0.005) but no significant changes of OAB symptom scores were reported. PFMT was more effective than conservative advice in decreasing the ICIQ symptom score (MD, -1.12, 95 % CI -2.13 to -0.11, 2 trials, 91 patients, p = 0.03), although the number of incontinence episodes was not significantly different between groups. Conclusions: The results of the meta-analysis demonstrate a moderate efficacy of all considered treatments without proving the superiority of one therapy over the others. Combination treatment using different pharmacological and non-pharmacological therapies could achieve the best clinical efficacy due to the favorable combination of the different mechanisms of action. This could be associated with fewer side effects due to drug dosage reduction. These data are only provisional and should be considered with caution, due to the few studies included in metaanalysis and to the small number of patients.
47
Baser, Aykut, Ali Ersin Zumrutbas, Yusuf Ozlulerden, et al. "Is There a Correlation Between Behçet Disease and Lower Urinary Tract Symptoms?" International Neurourology Journal 24, no. 2 (2020): 150–55. http://dx.doi.org/10.5213/inj.2040004.002.
Full textAbstract:
Purpose: In this study, we aimed to determine the prevalence of lower urinary tract symptoms (LUTS) in patients with Behçet disease (BD) and to investigate the relationship between the severity of BD and LUTS.Methods: Fifty-five patients with BD were included in this study from January to December 2018. All patients received a detailed urological evaluation. Additionally, BD activity was investigated using the Behçet Disease Current Activation Form. The International Prostate Symptom Score (IPSS), International Consultation on Incontinence Questionnaire Short Form, 8-item overactive bladder questionnaire forms, uroflowmetry, and postvoid residual urine volume were evaluated.Results: The mean age of the patients was 42.6 years. The mean activity score of BD was 4.6±3.2 and the mean IPSS score was 7.3±7.3. Sex had no significant effect on the BD activity score. The BD activity score was significantly correlated with the IPSS score, frequency of daytime urination, nocturia, and urgency. It was also correlated with the presence and the severity of urinary incontinence and the effect of urinary incontinence on daily life. Peak flow rate, voided volume, and the postvoid residual urine volume were not correlated with the BD activity score.Conclusions: LUTS were highly prevalent in patients with BD, and the severity and current activity of BD were correlated with frequency, nocturia, urgency, and urinary incontinence. Therefore, a urological evaluation of patients with BD in whom the activity and severity of the disease is elevated should be carried out comprehensively and patients should be managed accordingly.
48
Sharma, Jai B., Mukul Chauhan, Neerja Bhatla, et al. "Correlation of incontinence impact questionnaire score in overactive bladder syndrome cases with urodynamic findings." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 10, no. 1 (2020): 290. http://dx.doi.org/10.18203/2320-1770.ijrcog20205784.
Full textAbstract:
Background: Overactive bladder syndrome (OAB) is a common condition. The aim of the present study was to correlate the incontinence impact questionnaire (IIQ) score with urodynamic studies in patients of overactive bladder syndrome.Methods: It was a prospective study performed in a tertiary referral centre on 60 women with symptomatology of OAB. IIQ score was calculated and urodynamic studies were performed in all patients in which detrusor overactivity, maximum flow rate of urine per second (Qmax) and voiding time in seconds was calculated in all women.Results: The mean age was 42.3±9.91 years, mean body mass index was 24.7±2.71 kg/m2, mean parity was 2.4 and mean serum creatinine level was 0.84±0.21 mg/dl. Symptoms seen were urgency (100%), frequency (100%), urge incontinence (95.0%) and nocturia (76.6%). IIQ score ranged from 7-20 with mean being 12.27±3.38. OAB was mild in 36.6%, moderate in 41.66% and severe in 21.66% patients. On urodynamic studies, detrusor overactivity was present in 75% cases being 59% in mild, 80% in moderate and 76.92% in severe OAB. Mean Qmax increased with severity of OAB and was 29.55ml/second in mild OAB, 30.36ml/second in moderate OAB and 31.59 ml/second in severe OAB. Mean voiding time decreased with severity of OAB and was 33.44 seconds in mild OAB, 32.14 seconds in moderate OAB and 31.47 seconds in severe OAB.Conclusions: IIQ score and urodynamic studies are useful in diagnosis and quantification of OAB syndrome.
49
Razaq, Hiba H., Mohammed B. Ismail, and Mohamed E. Abdelrhman. "Mirabegron in the Management of Overactive Bladder Syndrome in Ghazi Al-Hariri Hospital." Journal of the Faculty of Medicine Baghdad 67, no. 1 (2025): 61–65. https://doi.org/10.32007/jfacmedbaghdad2451.
Full textAbstract:
Background: An individual’s quality of life is adversely affected by overactive bladder (OAB) symptoms. The key element that characterizes OAB is urgency which together with nocturia and urge urinary incontinence, are considered the most irksome symptoms. The side effects of the anticholinergic medication have caused a significant number of patients to discontinue their treatment. More recently, there has been research conducted on the potential correlation between an anticholinergic burden and the development of dementia. The detrusor muscle has been demonstrated to relax as a result of the activation of β3 adrenoceptors, which in turn facilitated the development of the first β3 adrenoceptor agonist. Mirabegron is the initial medication in this category to receive approval for the treatment of an overactive bladder. Objectives: To explore the effect of mirabegron on bladder capacity in patients with OAB. Methods: A case series study was performed on 40 patients diagnosed with OAB from October 2023 to March 2024 in the Medical City Complex (Ghazi AL-Hariri Hospital) Urology Outpatient Clinic. These patients took a single dose of mirabegron 50 mg per day for four months and were assessed for the effect of this drug on the bladder capacity measurement, in milliliters, measured by ultrasound. Result: Following treatment with mirabegron, a statistically significant increase in bladder capacity was found from the baseline level after two and four months. Conclusion: Mirabegron is an effective drug for the treatment of OAB, as it increases bladder capacity.
50
Lu, Jian-He, Kuang-Shun Chueh, Shu-Mien Chuang, et al. "Low Intensity Extracorporeal Shock Wave Therapy as a Potential Treatment for Overactive Bladder Syndrome." Biology 10, no. 6 (2021): 540. http://dx.doi.org/10.3390/biology10060540.
Full textAbstract:
Background: The present study attempted to investigate the therapeutic effect and duration of low intensity extracorporeal shock wave therapy (LiESWT) on overactive bladder (OAB) symptoms, including social activity and the quality of life (QoL). Methods: In this prospective, randomized, single-blinded clinical trial, 65 participants with OAB symptom were randomly divided into receive LiESWT (0.25 mJ/mm2, 3000 pulses, 3 pulses/second) once a week for 8 weeks, or an identical sham LiESWT treatment without the energy transmission. We analyzed the difference in overactive bladder symptom score (OABSS) and 3-day urinary diary as the primary end. The secondary endpoint consisted of the change in uroflowmetry, post-voided residual (PVR) urine, and validated standardized questionnaires at the baseline (W0), 4-week (W4) and 8-week (W8) of LiESWT, and 1-month (F1), 3-month (F3) and 6-month (F6) follow-up after LiESWT. Results: 8-week LiESWT could significantly decrease urinary frequency, nocturia, urgency, and PVR volume, but meaningfully increase functional bladder capacity, average voided volume and maximal flow rate (Qmax) as compared with the W0 in the LiESWT group. In addition, the scores calculated from questionnaires were meaningfully reduced at W4, W8, F1, F3, and F6 in the LiESWT group. Conclusions: Our results revealed that the therapeutic efficacy of LiESWT could improve voided volume and ameliorate OAB symptoms, such as urgency, frequency, nocturia, and urinary incontinence, and lasted up to 6 month of follow-up. Moreover, LiESWT treatment brought statistically significant and clinically meaningful improvements in social activity and QoL of patients. These findings suggested that LiESWT could serve as an alternative non-invasive therapy for OAB patients.